8 Investor presentation First nine months of 2020 Ozempic® and Rybelsus® continu TRx market leadership in the US US GLP-1 NBRx market share NBRx share 70% 60% Ozempic® NN GLP-1 Rybelsus® Victoza® dulaglutide 60.2% 50% 40% 34.7% 30% 34.5% 20% 13.5% 10% 12.0% 0% Jun 2019 Oct 2020 Source: NBRx-IQVIA National LRx Weekly, Sep 2020 NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk
Download PDF file